Exploring Hcc Managing Patients On Frontline Systemic Therapy
Let's dive into the details surrounding Hcc Managing Patients On Frontline Systemic Therapy.
- Ghassan K. Abou-Alfa, MD, reviews the details of a case of a 70-year-old man with metastatic
- Matthew S. Davids, MD, MMSc; William Wierda, MD, PhD; and Nitin Jain, MD, discuss the
- ... for selecting lenvatinib, sorafenib, or Y-90 are provided in the context of
- Richard S. Finn, MD, discusses his personal experience with regorafenib and nivolumab for his
- Catherine T. Frenette, MD, and Darren S. Sigal, MD, discuss when it is the right time to move to
In-Depth Information on Hcc Managing Patients On Frontline Systemic Therapy
Panelists Richard S. Finn, MD, and Arndt Vogel, MD, PhD, discuss the Panelists Richard S. Finn, MD; Richard H. Marshall, MD; and Jordi Bruix, MD; review recent clinical evidence with Panelists Ghassan K. Abou-Alfa, MD; Amit G. Singal, MD; and Richard Finn, MD, outline A discussion on initiating
Madappa Kundranda, MD, PhD, a medical oncologist at Banner MD Anderson Cancer Center, discusses the
That wraps up our extensive overview of Hcc Managing Patients On Frontline Systemic Therapy.
